BUSINESS ACQUISITIONS	3 Months Ended
Mar. 31, 2022
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	BUSINESS ACQUISITIONS On February 18, 2022, the Company closed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products, for approximately $455.1 in cash. The purchase considerations for this acquisition have been allocated under the acquisition method of accounting to the estimated fair market value of the net assets acquired, including approximately $270.0 in identifiable intangible assets and a residual amount of non-tax deductible goodwill of approximately $286.2. The amortization period for technology intangible assets acquired from this business is 12 years. The acquisition was made primarily to complement and accelerate the Company’s existing liquid biopsy capabilities and expand the Company’s leading oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities. The transaction includes two milestone earnout payments, with one based on the successful development of the in-process testing and the other based on revenue. The Company has recorded an estimate of $90.0 for this contingent consideration. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The preliminary valuation of acquired assets and assumed liabilities, include the following:

BUSINESS ACQUISITIONS

3 Months Ended

Mar. 31, 2022

Business Combination Disclosure [Text Block]

BUSINESS ACQUISITIONS On February 18, 2022, the Company closed its acquisition of Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics with a portfolio of comprehensive liquid biopsy and tissue-based products, for approximately $455.1 in cash. The purchase considerations for this acquisition have been allocated under the acquisition method of accounting to the estimated fair market value of the net assets acquired, including approximately $270.0 in identifiable intangible assets and a residual amount of non-tax deductible goodwill of approximately $286.2. The amortization period for technology intangible assets acquired from this business is 12 years. The acquisition was made primarily to complement and accelerate the Company’s existing liquid biopsy capabilities and expand the Company’s leading oncology portfolio of next-generation sequencing (NGS)-based genomic profiling capabilities. The transaction includes two milestone earnout payments, with one based on the successful development of the in-process testing and the other based on revenue. The Company has recorded an estimate of $90.0 for this contingent consideration. The excess of the fair value of the consideration conveyed over the fair value of the net assets acquired was recorded as goodwill. The preliminary valuation of acquired assets and assumed liabilities, include the following: